Gilead Sciences (GILD) : Forte Capital Adv scooped up 151 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 11, 2016. The investment management firm now holds a total of 49,778 shares of Gilead Sciences which is valued at $4,268,464.Gilead Sciences makes up approximately 1.61% of Forte Capital Adv’s portfolio.
Other Hedge Funds, Including , R.h. Dinel Investment Counsel reduced its stake in GILD by selling 600 shares or 3.58% in the most recent quarter. The Hedge Fund company now holds 16,175 shares of GILD which is valued at $1,387,006. Gilead Sciences makes up approx 1.59% of R.h. Dinel Investment Counsel’s portfolio.Chevy Chase Trust Holdings reduced its stake in GILD by selling 17,407 shares or 1.5% in the most recent quarter. The Hedge Fund company now holds 1,143,356 shares of GILD which is valued at $98,957,462. Gilead Sciences makes up approx 0.54% of Chevy Chase Trust Holdings’s portfolio. Iowa State Bank added GILD to its portfolio by purchasing 136 company shares during the most recent quarter which is valued at $11,771. Gilead Sciences makes up approx 0.01% of Iowa State Bank’s portfolio.Cullinan Associates Inc boosted its stake in GILD in the latest quarter, The investment management firm added 1,406 additional shares and now holds a total of 51,328 shares of Gilead Sciences which is valued at $4,355,694. Gilead Sciences makes up approx 0.35% of Cullinan Associates Inc’s portfolio.
Gilead Sciences closed down -0.88 points or -1.02% at $85.75 with 83,34,368 shares getting traded on Wednesday. Post opening the session at $86.71, the shares hit an intraday low of $85.72 and an intraday high of $87.08 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.